Target intelligence / Profile preview

TMEM9 domain family member B (TMEM9B)

Target
TMEM9B
Molecular classification
Type I transmembrane protein, Lysosomal/endosomal accessory protein, Regulatory protein for chloride/proton exchangers
01

Overview

TMEM9 domain family member B (TMEM9B) is a single-span, glycosylated type I transmembrane protein primarily localized to intracellular acidic organelles such as lysosomes and endosomes. TMEM9B directly interacts with endosomal ClC-3 and ClC-4 chloride/proton transporters, inhibiting their function and modulating their activation kinetics. It is involved in the positive regulation of NF-κB and TNF-α signaling pathways, and its expression is associated with both neurodevelopmental and inflammatory conditions, including certain cancers and autoimmune diseases such as Wegener's granulomatosis. TMEM9B’s function suggests a role as a regulatory protein influencing membrane trafficking, cytokine production, and local inflammatory responses, making it a potential biomarker and therapeutic target in diseases related to membrane transporter homeostasis and immune dysregulation

Other names
C11orf152310004K06RIKD7H11orf15TMEM9 domain family, member BTMEM9BUNQ712/PRO1375ICRFP703B1614Q5.3RGD1310775
02

Mechanism of action

Inhibition or modulation of endosomal/lysosomal Cl─/H⁺ transporter function, regulation of NF-κB and TNF-α signaling, and transcriptional control of cytokine production

03

Biological functions

Regulation of endosomal/lysosomal ClC-3 and ClC-4 transporter activityPositive regulation of canonical NF-κB signal transductionModulation of TNF-α activationTranscriptional control of cytokine productionInteraction with vesicular H⁺-ATPase
04

Disease associations

Cancer (enhanced expression linked to various types via vesicular H⁺-ATPase interaction)Autoimmune/inflammatory disease (Wegener’s granulomatosis/vasculitis, due to antigenicity and TNF-α regulation)Neurodevelopmental disorders (potentially implicated via control of neuronal endosomal transporters)
05

Safety considerations

None documented in the available literature; knockout mouse studies showed no overt phenotype, but therapeutic targeting may require caution due to possible impacts on endosomal/lysosomal homeostasis and immune regulation
06

Biomarkers

TMEM9B may serve as a biomarker for Wegener’s granulomatosis/vasculitis due to its recognition by autoantibodies and role in inflammatory signaling

Beyond the preview

Go deeper on TMEM9 domain family member B (TMEM9B).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on TMEM9 domain family member B (TMEM9B).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call